Monitoring allergen immunotherapy in allergic rhinitis; is nasal fluid the way to precision medicine?

Monitoring allergen immunotherapy in allergic rhinitis; is nasal fluid the way to precision medicine? - Monitoring allergen immunotherapy in allergic rhinitis.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON52036

Enrollment

Registered

2021-09-01

Start date

2023-09-20

Completion date

Unknown

Last updated

2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hay fever rhinitis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: a. Age >= 18 years b. IgE-sensitized birch pollen allergic based on: - sIgE tree pollen > 10 kU/L - seasonal related allergic rhinitis c. Start of Itulazax therapy or standard therapy (nasal corticosteroid and/or antihistamine eye drops) d. Signed informed consent.

Exclusion criteria

Exclusion criteria: a. Age

Design outcomes

Primary

Measure	Time frame
Comparison of BAT outcomes (degree of inhibition) with nasal fluid BAT and serum BAT of treated and control patients at baseline and during AIT at 8 and 16 weeks.	—

Secondary

Measure	Time frame
Correlation between the degree of inhibition in the BAT with the degree of increase of IgG4/IgA-associated inhibitory activity in nasal fluid and serum on IgE-FAB to B-cells.	—

Countries

Netherlands

Outcome results